Compounding Pharmacy Regulation and Office Use

Published Online: Thursday, November 14, 2013
Follow Pharmacy_Times:
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses his concern that in reaffirming section 503A of the Federal Food, Drug, and Cosmetic Act, H.R. 3204 (the Drug Quality and Security Act) would leave pharmacists who compound medications for office use by physicians and dentists in an ambiguous regulatory position. This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.

Related Articles
The federal Drug Quality and Security Act was signed into law in 2013 with the intent to hold pharmacy stakeholders accountable for identifying suspect drug products and reporting related issues.
Beneficiary Advisory Panel Decision Sets Stage for Continued Coverage; Final Decision Rests with TRICARE Management Activity Director
Dale Coker, RPh, FIACP, owner/pharmacist of Cherokee Custom Script Pharmacy, in Canton, Ga., has been elected President to the 2015 International Academy of Compounding Pharmacists Board of Directors by the IACP membership. Mr. Coker will serve as President through January 2016.
Expanding upon efforts to implement the federal Drug Quality and Security Act enacted 1 year ago, the FDA today released 3 policy documents that assist companies that compound sterile drugs with registering as outsourcing facilities.
Latest Issues
$auto_registration$